###### Strengths and limitations of this study

-   Only randomised controlled clinical trials were included.

-   Participant-unit data were used for syntheses.

-   Subgroup analyses by follow-up length and categories of complications were performed.

-   Serious risks of bias were found within and across studies and the quality of evidence was only low to moderate.

Introduction {#s1}
============

Dental implants supporting prosthesis are commonly considered a promising method for the rehabilitation of missing teeth.[@R1] However, dental implantation in the posterior maxilla is usually challenging due to insufficient vertical bone volume, poor bone quality, limited visibility, reduced interarch space and sinus pneumatisation.[@R4] These conditions are exacerbated if patients have a history of wearing removable dentures.[@R6]

To achieve sufficient vertical bone volume in the posterior maxilla, sinus floor elevation using the lateral window approach or the osteotomy technique has been introduced and widely used over the past 40 years.[@R7] The lateral window approach is commonly used in dental implantation procedures.[@R9] Using these techniques with or without bone grafting, conventional implants can be placed in the elevated sites. The implant success rate is typically greater than 90% in long-term evaluation.[@R10] However, sinus floor elevation surgery is usually associated with higher cost, more complicated surgical procedures and a high prevalence of complications such as infection, sinus membrane perforation and graft failure.[@R13] In addition, the clinical outcome of sinus floor elevation can also be restricted by extremely insufficient residual bone height, abnormal sinus anatomy, thickening of the sinus membrane, stability of the grafted bone and the number of missing teeth.[@R13]

Short implants with improved implant design and surface properties have been successfully applied as an alternative to sinus floor elevation surgery and have shown good results in posterior maxilla. Implants ≤10 mm,[@R19] ≤8 mm,[@R20] ≤7 mm[@R21] and 6--8 mm[@R22] are reported to have survival rates comparable to those of longer implants. In addition, short implants ≤6 mm in length have been introduced as another alternative in atrophic posterior maxilla.[@R6] Short implants require a less complicated surgical approach and could be used in cases when sinus floor elevation surgery is not applicable,[@R25] especially in cases of maxillary sinusitis, maxillary cyst, large vessels and other cases involving abnormal sinus anatomy. Studies have explored the short-term and long-term survival rates of short implants (≤6 mm).[@R26] Unfortunately, the evidence supporting the use of short implants (≤6 mm) in the posterior maxilla is weak, and no guideline statement is currently recommended.

The present systematic review aims to compare the effectiveness of short implants (≤6 mm) and longer implants (≥10 mm) with sinus floor elevation in atrophic posterior maxilla. Our null hypothesis was that the survival rate, patient satisfaction, marginal bone loss (MBL) and surgery-related complications of short implants (≤6 mm) were comparable to longer implants in combination with sinus floor elevation.

Materials and methods {#s2}
=====================

Protocol and registration {#s2-1}
-------------------------

This systematic review and meta-analysis was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines.[@R31]

Eligible criteria {#s2-2}
-----------------

Randomised controlled trials (RCTs) meeting the following predetermined inclusion criteria (PICOS format) were included:

-   Population: Partially edentulous patients in the premolar and molar regions of the maxilla, for whom the residual bone height in the atrophic posterior maxilla was sufficient for the insertion of a short implant (≤6 mm) but insufficient for the insertion of longer implants.

-   Intervention: One or more short implants (≤6 mm) were placed in the posterior maxilla without sinus floor elevation in the short implant group.

-   Comparison: One or more longer implants were placed in the posterior maxilla after sinus floor elevation by any technique in the elevation group.

-   Outcomes: The primary (survival rate) and secondary (MBL, complications and patient satisfaction) outcomes of interest were measured, with a follow-up length of 1 year or longer postloading.

Information sources and search strategies {#s2-3}
-----------------------------------------

Two content experts (QY and XW) searched PubMed, Embase and the Cochrane CENTRAL (The Cochrane Central Registration of Controlled Trials) for RCTs, independently and in duplicate. The last search was conducted on 31 May 2018. A methodologist (FH) was consulted to resolve any disagreements. Main search terms included: "dental implant", "short implant", "ultrashort", "alveolar bone loss", "atrophic maxilla", "sinus lift", and "sinus floor elevation". No restriction was set regarding publication year, publication language or status. The detailed search strategies are listed in the [online supplementary file](#SP1){ref-type="supplementary-material"}. In addition, retrospective and prospective searches were conducted by checking the reference lists of key articles and studies citing these key articles, using Google Scholar.
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Study selection and data collection {#s2-4}
-----------------------------------

Two review authors (QY and XW) conducted the study selection independently and in duplicate. The titles and abstracts of all records were scanned. Full texts of studies were obtained in cases they appeared to meet the inclusion criteria or further information were needed to determine eligibility. Studies excluded at this or subsequent stages were recorded with the reasons for exclusion. All disagreements were resolved by discussion.

Two review authors (QY and XW) extracted the data independently and in duplicate using specifically designed data extraction forms. The extracted data included citation details (year of publication, country of origin, setting and source of funding), details on the participants (demographic characteristics, residual bone height and inclusion criteria), details of intervention (implant length, diameter, brand, surface structure, surgical method, follow-up time, prosthesis type), outcome assessment, sample size calculation and trial registration. Corresponding authors were contacted for missing data or information.

Risk of bias of included studies {#s2-5}
--------------------------------

Two authors (QY and XW) assessed the risk of bias of each included study independently and in duplicate using the Cochrane risk of bias assessment tool for RCTs.[@R32] Disagreements were resolved through discussion. A third review author (FH) was consulted when necessary. Seven domains were assessed, including sequence generation (selection bias), allocation concealment (selection bias), blinding of participants and personnel (performance bias), blinding of outcome assessment (detection bias), incomplete outcome data (attrition bias), selective outcome reporting (reporting bias) and other bias (factors that had potential influence on outcomes but were not evenly distributed across groups or not clearly reported, such as the manufacturer or diameter of implants). Individual studies were categorised as having low, high or unclear risk of bias. The risk of bias across studies was determined according to the risk of bias in each included study.

Assessment of heterogeneity {#s2-6}
---------------------------

Clinical heterogeneity among the included studies was assessed by comparing study design, participant conditions (gender, age, residual bone height), intervention (implant length, diameter, surface structure, surgical method) and outcome measures. Statistical heterogeneity was evaluated using Cochrane's Q test and the I² statistic. In the Q test, a p\<0.1 was considered an indication of significant heterogeneity.

Assessment of publication bias {#s2-7}
------------------------------

If at least 10 studies were included in a meta-analysis, We would have used a funnel plot and the Egger's test[@R33] asymmetry to assess the potential existence of publication bias if at least ten studies were included in a meta-analysis.

Synthesis of results {#s2-8}
--------------------

The unit of analysis was set as participant rather than implant.[@R34] RevMan V.5.3 software was used for data synthesis. Meta-analyses were undertaken only when at least two studies that made similar comparisons reported the same outcomes. The effect measures were risk ratio (RR) for dichotomous outcomes (implant survival and complications) and mean difference (MD) for continuous outcomes (MBL). RR was calculated through Mantel-Haenszel analysis and MD was calculated through inverse variance. P\<0.05 was considered statistically significant. The fixed-effect model was used when fewer than four studies were included in a meta-analysis, and the random-effects model was used when four or more studies were included.[@R35]

Additional analysis {#s2-9}
-------------------

Subgroup analysis by length of follow-up was performed to control for the possibility that function time might influence implant survival.[@R39] In addition, subgroup analysis by categories of complications was performed. Complications were categorised according to into postsurgery reaction (bleeding, swelling and discomfort), biological complications (sinus perforation or infection, implant mobile, peri-implant mucositis and peri-implantitis) and technical complications (complications related to screws and crowns). If risks of bias in some studies were serious, we performed sensitivity analysis by excluding these studies. Considering only three studies were included in the MBL 3 years or longer follow-up but the meta-analysis for MBL included more than three studies, a sensitivity analysis was conducted for MBL by using fixed-effect model.

Summary of findings {#s2-10}
-------------------

Grading of Recommendations Assessment, Development and Evaluation approach[@R40] was adopted to evaluate quality of evidence in this systematic review. A summary of findings table was made with an online tool (cebgrade.mcmaster.ca/gradepro.html). Outcomes were evaluated including survival rate and MBL of one to table was made with an online tool (cebgrade.mcmaster.ca/gradepro.html). Outcomes were evaluated including survival rate and MBL of 1--3 years and 3 years or longer follow-up, and complications. Five domains in quality of evidence were assessed: the overall risk of bias, directness of evidence, consistency of results, precision of estimates, as well as the risk of publication bias. The quality of the body of evidence was classified into four categories: high, moderate, low and very low.

Patient and public involvement {#s2-11}
------------------------------

No patient or public was involved in this systematic review.

Results {#s3}
=======

Study selection {#s3-1}
---------------

Electronic searches identified a total of 879 titles and abstracts in PubMed and 251 in Embase. After removal of duplicates, the titles and abstracts of 1013 unique items were screened. We then retrieved the full texts of 25 potentially eligible articles, of which 20 were excluded for the reasons described in [figure 1](#F1){ref-type="fig"}. Retrospective and prospective hand searches yielded two more articles. Finally, seven studies[@R29] met our eligibility criteria and were included in this review ([figure 1](#F1){ref-type="fig"}).

![Flow diagram for study selection. RCT, randomised controlled trial.](bmjopen-2019-029826f01){#F1}

Study characteristics {#s3-2}
---------------------

The characteristics of the seven included studies are listed in [table 1](#T1){ref-type="table"}. One study was a split-mouth trial, and the rest were two-arm parallel RCTs. The length of follow-up ranged from 1 to 3 years. For sinus floor elevation, either osteotomy-mediated sinus floor elevation or the lateral window technique was adopted. In two studies, single crowns were used as the rehabilitation method; in the remaining studies, single crowns or splinted prosthetics were used. The outcome measures used in these studies included implant failure, MBL, complications and patient satisfaction. Overall, 171 participants were included in the short implant groups, and 159 participants were included in the elevation groups.

###### 

Characteristics of the included studies

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                          Design      Subjects     Follow-up period PL   Short implant group   Elevation group   Rehabilitation methods   Outcome measures                                                                                       
  ------------------------------ ----------- ------------ --------------------- --------------------- ----------------- ------------------------ ------------------ ---------- ---- ------------------ ---------- -------------------------- ---------- -------------------
  Bolle *et al*, 2018[@R29]      RCT (TAP)   INT 7/13\    59.35 (47--73)\       4--5                  1 year            37                       4                  4 or 4.5   41   10, 11.5, 13       4 or 4.5   Osteotomy approach         SG or SP   NIF, MBL, COM
                                             CON 12/8     63.25 (46--72)                                                                                                                                                                                

  Gastaldi *et al*, 2018[@R41]   RCT (TAP)   INT 3/17\    58.6 (39--80)\        4--6                  3 years           20                       5                  5          20   10, 11.5, 13, 15   5          Lateral window technique   SG or SP   NIF, MBL, COM
                                             CON 7/13     52.8 (42--70)                                                                                                                                                                                 

  Gastaldi *et al*, 2017[@R42]   RCT (TAP)   INT 3/7\     53.4 (43--67)\        5--7                  3 years           16                       5 or 6             5          18   10                 5          Osteotomy approach         SG or SP   NIF, MBL, COM, PS
                                             CON 5/5      58.6 (48--70)                                                                                                                                                                                 

  Guljé *et al*, 2014[@R43]      RCT (TAP)   INT 7/14\    50 (30--71)\          6--8                  1 year            21                       6                  4          20   11                 4          Lateral window technique   SG         NIF, MBL, COM, PS
                                             CON 13/7     48 (29--72)                                                                                                                                                                                   

  Pohl *et al*, 2017[@R44]       RCT (TAP)   49/52\*      50.5 (20--75)\*--     5--7                  3 years           67                       6                  4          70   11, 13, 15         4          Lateral window technique   SG         NIF, MBL, COM

  Felice *et al*, 2018[@R45]     RCT (SM)    11/9         57.6 (45--80)         5--7                  3 years           39                       6                  4          44   10, 11.5, 13, 15   4          Lateral window technique   SG or SP   NIF, MBL, COM

  Bechara *et al*, 2017[@R46]    RCT (TAP)   INT 10/23\   47.5±16.2\            ≥4                    3 years           45                       6                  4--8       45   10, 11.5, 13, 15   4--8       Lateral window technique   SG or SP   NIF, MBL, COM, PS
                                             CON 9/11     49.2±13.4                                                                                                                                                                                     
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*Details for subject information in intervention and control group were not reported.

COM, complications; CON, control; DIA, implant diameter; INT, intervention; LEN, implant length; MBL, marginal bone loss; NIF, number of implant failures; NR, not reported; PL, postloading; PS, patient satisfaction;RBH, residual bone width under sinus floor;RCT, randomised controlled trial; SG, single crowns; SM, split mouth; SP, splinted prosthetics; TAP, two arm parallel.

Risk of bias assessment {#s3-3}
-----------------------

The results of the risks of bias assessment are shown in [figures 2 and 3](#F2 F3){ref-type="fig"}. Selection bias and performance bias were assessed as low in all but one study by Bachara *et al* [@R46] due to inadequate description on random sequence generation and blinding of participants. For detection bias, most studies showed high risks because assessors could recognise sites that underwent sinus floor elevation. For attrition bias, three studies[@R42] was assessed as high. Two studies[@R44] showed high risk of reporting bias. Other risks of bias were considered high or unclear in three studies. Overall, all included studies were at high risk of bias for at least one domain ([table 2](#T2){ref-type="table"}).

![Risk of bias in each included study.](bmjopen-2019-029826f02){#F2}

![Risk of bias across included studies.](bmjopen-2019-029826f03){#F3}

###### 

Details on the risk of bias for each included study

  Study                          Random sequence generation                                                                                                        Allocation concealment                                                                                                                            Blinding of patients/carers                                                                                                                               Blinding of outcome assessment                                                                                                                                                                                                    Incomplete outcome data                                                                                                                    Selective reporting                                                                                                   Other
  ------------------------------ --------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------ --------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------
  Bolle *et al*, 2018[@R29]      Low risk---quote: 'a computer-generated restricted randomisation list'                                                            Low risk-quote: 'the information on how to treat each patient was enclosed in sequentially numbered, identical, opaque, sealed envelopes.'        Low risk---quote: 'treatment allocation was concealed to the investigators in charge of enrolling and treating the patients.'                             High risk---quote: 'complications were dealt with directly and reported by the responsible clinicians, who were not blinded'; 'augmented sites could be easily identified on radiographs due to the different implant lengths.'   Low risk---quote: 'one patient from the short implant group and one from elevation group dropped out.'                                     Low risk---comment; All outcome measure in methods were reported in results                                           Unclear risk---comment: diameter of implants (4 mm or 4.5 mm) was not controlled
  Gastaldi *et al*, 2018[@R41]   Low risk---quote: 'a computer-generated restricted randomisation list'                                                            Low risk---quote: 'The randomised codes were enclosed in sequentially numbered, identical, opaque, sealed envelopes'                              Low risk---quote: 'treatment allocation was concealed to the investigators in charge of enrolling and treating the patients.'                             High risk---quote: 'augmented sites could be easily identified because of the different anatomy of the two sides after the augmentation procedure'                                                                                Low risk---omment: one patient dropped out of the short implant group (1/20), and two patients dropped out of the elevation group (2/20)   Low risk---comment; All outcome measures in methods were reported in results                                          Unclear risk---comment: information of short implants was not reported
  Gastaldi *et al*, 2017[@R42]   Low risk---quote: 'a computer-generated restricted randomisation list'                                                            Low risk---quote: 'The randomised codes were enclosed in sequentially numbered, identical, opaque, sealed envelopes.'                             Low risk---quote: 'treatment allocation was concealed to the investigators in charge of enrolling and treating the patients'                              High risk---quote: 'sinus-lifted sites could be identified on radiographs because they appeared more radio- opaque and implants were longer.'                                                                                     High risk---comment: no patients dropped out of the short implant group (0/10); two patients dropped out of the elevation group (2/10)     Low risk---comment; All outcome measures in methods were reported in results                                          Low risk
  Guljé *et al*, 2014[@R43]      Low risk---quote: 'Randomisation was performed using a block randomization sequence to provide equal distribution of subjects.'   Low risk---quote: 'A sealed envelope'                                                                                                             Low risk---quote: 'A sealed envelope was opened by the surgical assistant at the beginning of the surgical procedure.'                                    High risk---quote: 'blinding was possible in the clinical evaluation but not during analysis of the radiographs.'                                                                                                                 Low risk---comment: no patient dropped out of the short implant group (0/21); one patient in the elevation group died (1/20)               Low risk---omment; All outcome measures in methods were reported in results                                           Low risk
  Pohl *et al*, 2017[@R44]       Low risk---quote: 'A block randomization sequence was used to provide an equal distribution'                                      Low risk---quote: 'A sealed envelope'                                                                                                             Low risk---quote: 'After flap elevation, a sealed randomisation envelope was opened to allocate the subject to either one of the two treatment groups.'   Unclear risk---quote: 'an independent examiner performed all the radiographic measurements.' Other information was not reported.                                                                                                  High risk---comment: The reasons for incomplete reporting of MBL were not provided.                                                        High risk---comment: MBL at 3-year follow-up was reported at the implant level rather than at the participant level   Low risk
  Felice *et al*, 2018[@R45]     Low risk---quote: 'a computer-generated restricted randomisation list'                                                            Low risk---quote: 'The information on how to treat site number one was enclosed in sequentially numbered, identical, opaque, sealed envelopes.'   Low risk---quote: 'Treatment allocation was concealed to the investigators in charge of enrolling and treating the patients.'                             High risk---quote: 'augmented sites could be easily identified because of the different anatomy'                                                                                                                                  High risk---comment: it was a split-mouth design study, and two drop-outs (2/20) occurred                                                  Low risk---comment: All outcome measures in methods were reported in results                                          Low risk
  Bechara *et al*, 2017[@R46]    Unclear risk---quote: 'Patients were randomly assigned'                                                                           Low risk---quote: 'a sequentially numbered sealed envelope'                                                                                       Unclear risk---comment: not mentioned                                                                                                                     Unclear risk---quote: 'At each annual inspection, an experienced, calibrated, independent examiner performed a careful clinical examination', but elevation site can be distinguished                                             Low risk---comment: one patient dropped out of the short implant group (1/33), and one patient dropped out of the elevation group (1/20)   High risk---comment: MBL was reported at the implant level rather than at the participant level                       High risk---comment: diameter of implants was not controlled (4--8 mm)

MBL, marginal bone loss.

Synthesis of results {#s3-4}
--------------------

### Survival rate {#s3-4-1}

[Figure 4](#F4){ref-type="fig"} shows the results of a meta-analysis for participant unit implant survival rate with a subgroup analysis based on length of follow-up. Five studies reported 100% survival of short implants (≤6 mm) within the study period. For this outcome, there was no evidence of a difference between the short implant group and the elevation group either 1--3 years postloading (RR 1.01, 95% CI 0.97 to 1.04, p=0.74, I²=0%, seven RCTs, 321participants) or 3 years or longer postloading (RR 1.00, 95% CI 0.97 to 1.04, p=0.79, I²=0%, five RCTs, 237 participants). Further details of the implant failures are summarised in [table 3](#T3){ref-type="table"}.

![Forest plot for implant survival rate. M-H, Mantel-Haenszel; SI, short implant group; SFE, sinus floor elevation group.](bmjopen-2019-029826f04){#F4}

###### 

Details of implant failures reported in the included studies

  Study                          Short implant group   Elevation group                                                                                                                                                                                                                                        
  ------------------------------ --------------------- ----------------- ----- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------- ---------- ----- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Bolle *et al*, 2018[@R29]      4                     4 or 4.5          2/3   PAR1. One implant was mobile 3 months after placement, and another implant migrated into the sinus 4 months after placement. PAR2. One implant was medially tilted 2 weeks after placement   10,11.5,13       4 or 4.5   4/6   PAR1. One implant was mobile 2 months after placement because of a perforation of the sinus lining at its detachment. Another implant was mobile 2 months later. PAR2. One implant migrated into the sinus 3 months after placement. PAR3. Two implants were mobile 3 months after placement because the patient insisted on wearing her removable denture. PAR4. One implant was mobile, and the patient experienced discomfort when chewing 5 months postloading.
  Gastaldi *et al*, 2018[@R41]   5                     5                 1/1   PAR1. One implant failed 3 months postloading.                                                                                                                                               10,11.5, 13,15   5          0     None
  Felice *et al*, 2018[@R45]     6                     4                 0     None                                                                                                                                                                                         10,11.5, 13,15   4          1/2   PAR1. Two implants failed due to peri-implantitis 2 years postloading.
  Bechara *et al*, 2017[@R46]    6                     4--8              0     None                                                                                                                                                                                         10,11.5, 13,15   4--8       1/2   PAR1. Two implants were lost caused due to chronic sinus infection with loss of integration/implant stability 2 months after surgery.

DIA, implant diameter;LEN, implant length; PAR, participant; PAR/IMP, participant/implant.

### Marginal bone loss {#s3-4-2}

The results of the meta-analysis and subgroup analysis regarding peri-implant MBL are shown in [figure 5](#F5){ref-type="fig"}. A significant difference favouring the short implant group was found for both 1--3 years postloading (MD=−0.13, 95% CI −0.21 to 0.05; p=0.001, I²=87%, six RCTs, 249 participants) and 3 years or longer postloading (MD=−0.25, 95% CI −0.40 to 0.10; p=0.001, I²=0%, three RCTs, 88 participants). In sensitivity analysis by using fixed-effect model, results remained significant for both 1--3 years postloading (MD=−0.11, 95% CI −0.13 to 0.08; p\<0.001, I²=87%) and 3 years or longer postloading (MD=−0.25, 95% CI −0.40 to 0.10; p=0.001, I²=0%).

![Forest plot for marginal bone loss. SI, short implant group; SFE, sinus floor elevation group.](bmjopen-2019-029826f05){#F5}

### Complications {#s3-4-3}

Complications were categorised into postsurgery reaction, biological complications and technical complications ([table 4](#T4){ref-type="table"}). Short implant group was found with significantly less postsurgery reaction (RR 0.11, 95% CI 0.14 to 0.31, p\<0.001, I²=40%, three RCTs, 184 participants) and sinus perforation or infection (RR 0.11, 95% CI 0.02 to 0.63, p=0.01, I²=0%). Only one study[@R29] reported implant migrating into sinus in 5% patients (1/19) in short implant group while in 10.5% patients (2/19) in sinus floor elevation group. No statistically significant difference was found in other complications between short implants (≤6 mm) and longer implants.

###### 

Comparisons of complications

  Outcome or subgroup titles                     No of studies   No of participants   Statistical methods                Effect size
  ---------------------------------------------- --------------- -------------------- ---------------------------------- -----------------------
  Postsurgery reaction                           3               184                  Risk ratio (Fixed, M-H, 95% CI)    0.11 (0.14 to 0.31)\*
  Biological complications                                                                                               
   Sinus perforation or infection                3               125                  Risk ratio (Fixed, M-H, 95% CI)    0.11 (0.02 to 0.63)\*
   Implant mobile                                2               132                  Risk ratio (Fixed, M-H, 95% CI)    0.34 (0.06 to 2.06)
   Peri-implant mucositis and peri-implantitis   2               54                   Risk ratio (Fixed, M-H, 95% CI)    0.91 (0.14 to 5.79)
  Technical complications                                                             Risk ratio (Fixed, M-H, 95% CI)    
   Screw loosening                               3               169                  Risk ratio (Fixed, M-H, 95% CI)    2.66 (0.93 to 7.60)
   Crown loosening, decementation or chipping    5               223                  Risk ratio (Random, M-H, 95% CI)   1.22 (0.33 to 4.49)

\*Difference between the two groups was significant.

M-H, Mantel-Haenszel.

### Patient satisfaction {#s3-4-4}

Three studies[@R42] reported patient satisfaction. Meta-analysis was not conducted because methods of evaluating patient satisfaction were different. Guljé *et al* [@R43] used a questionnaire to evaluate patient satisfaction before surgery and 1 year postloading. Both groups showed improvement of satisfaction after crown placement. Gastaldi *et al* [@R42] evaluated patient satisfaction in function and aesthetic aspects. All patients in the short implant group (10) were satisfied with both function and aesthetic aspects. However, three patients in elevation group (3/10) were partially satisfied with function. Bechara *et al* [@R46] used a questionnaire evaluating patient satisfaction in function, aesthetic, cleaning of the implant-supported restorations, satisfaction and cost. Significantly more patients in short implant group expressed satisfaction in cost. In the other four aspects, no significant difference was found between short implant group and sinus floor elevation group.

Quality of evidence {#s3-5}
-------------------

For survival rate, the quality of evidence in both subgroups was downgraded by one level (moderate quality evidence) due to serious risks of bias. For short-term MBL (1--3 years follow-up), quality of evidence was downgraded by two levels for serious risks of bias and inconsistency. For long-term MBL (3 years or longer follow-up), quality of evidence was downgraded by one level for serious risks of bias. For complications, the quality of evidence in postsurgery reaction was moderate, downgrading by one level for serious risks of bias. The quality of evidence in other complications was low, downgrading by two levels for serious risks of bias and imprecision. Details are listed in [table 5](#T5){ref-type="table"}.

###### 

Summary of findings

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Short implant (≤6 mm) compared with longer implant (≥10 mm) with sinus floor elevation in atrophic posterior maxilla                                                                                                                                                                                                                                       
  ---------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------- ---------------------------------------------------------------------------------------------------- -------------------- ---------------------------- ----------- --
  **Patient or population**: atrophic posterior maxilla\                                                                                                                                                                                                                                                                                                     
  **Intervention**: short implant (≤6 mm)\                                                                                                                                                                                                                                                                                                                   
  **Comparison**: longer implant (≥10 mm) with sinus floor elevation                                                                                                                                                                                                                                                                                         

  Outcomes                                                                                                               **Anticipated absolute effects\*** (95% CI)                      Relative effect\                                                                                     № of participants\   Certainty of the evidence\   Comments    
                                                                                                                                                                                          (95% CI)                                                                                             (studies)            (GRADE)                                  

  Assumed risk† (elevation group)                                                                                        Corresponding risk\                                                                                                                                                                                                                 
                                                                                                                         (short implant group)                                                                                                                                                                                                               

  Survival rate follow-up: range 1--3 years                                                                              961 per 1000                                                     **970 per 1000**\                                                                                    **RR 1.01**\         321\                         ⨁⨁⨁◯\       
                                                                                                                                                                                          (932 to 999)                                                                                         (0.97 to 1.04)       (7 RCTs)                     MODERATE‡   

  Survival rate follow-up: range 3 years to longer years                                                                 982 per 1000                                                     **982 per 1000**\                                                                                    **RR 1.00**\         237\                         ⨁⨁⨁◯\       
                                                                                                                                                                                          (953 to 1000)                                                                                        (0.97 to 1.04)       (5 RCTs)                     MODERATE‡   

  Marginal bone loss follow-up: range 1--3 years                                                                         The mean marginal bone loss ranged from **0.1 to** **1.15** mm   The mean marginal bone loss in the intervention group was 0.13 mm lower (0.21 lower to 0.05 lower)   --                   249\                         ⨁⨁◯◯\       
                                                                                                                                                                                                                                                                                                                    (6 RCTs)                     LOW§        

  Marginal bone loss follow-up: range 3 years to longer years                                                            The mean marginal bone loss ranged from **1.08 to** **1.5** mm   The mean marginal bone loss in the intervention group was 0.25 mm lower (0.4 lower to 0.1 lower)     --                   88\                          ⨁⨁⨁◯\       
                                                                                                                                                                                                                                                                                                                    (3 RCTs)                     MODERATE‡   

  Postsurgery reaction                                                                                                   307 per 1000                                                     **34 per 1000**\                                                                                     **RR 0.11**\         184\                         ⨁⨁⨁◯\       
                                                                                                                                                                                          (12 to 59)                                                                                           (0.04 to 0.31)       (3 RCTs)                     MODERATE‡   

  Biological complications: sinus perforation or infection                                                               197 per 1000                                                     **20 per 1000**\                                                                                     **RR 0.11**\         125\                         ⨁⨁◯◯\       
                                                                                                                                                                                          (4 to 113)                                                                                           (0.02 to 0.63)       (3 RCTs)                     LOW¶        

  Biological complications: implant mobile                                                                               59 per 1000                                                      **20 per 1000**\                                                                                     **RR 0.34**\         132\                         ⨁⨁◯◯\       
                                                                                                                                                                                          (4 to 121)                                                                                           (0.06 to 2.06)       (2 RCTs)                     LOW¶        

  Biological complications: peri-implant mucositis or peri-implantitis                                                   200 per 1000                                                     **100 per 1000**\                                                                                    **RR 0.91**\         54\                          ⨁⨁◯◯\       
                                                                                                                                                                                          (10 to 934)                                                                                          (0.14 to 5.79)       (2 RCTs)                     LOW¶        

  Technical complications: screw loosening                                                                               81 per 1000                                                      **217 per 1000**\                                                                                    **RR 2.66**\         169\                         ⨁⨁◯◯\       
                                                                                                                                                                                          (76 to 916)                                                                                          (0.93 to 7.60)       (3 RCTs)                     LOW¶        

  Technical complications: crown loosening, decementation and chipping                                                   27 per 1000                                                      **33 per 1000**\                                                                                     **RR 1.22**\         223\                         ⨁⨁◯◯\       
                                                                                                                                                                                          (9 to 120)                                                                                           (0.33 to 4.49)       (5 RCTs)                     LOW¶        
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).

†Assumed risk is based on the overall event rate in the control groups of the included studies.

‡Downgraded one level due to serious risks of bias.

§Downgraded two levels due to serious risks of bias and serious inconsistency.

¶Downgraded two levels due to serious risks of bias and imprecision.

GRADE, Grading of Recommendations Assessment, Development, and Evaluation; RCTs, randomised controlled trials; RR, risk ratio.

Discussion {#s4}
==========

To the best of our knowledge, this is the first systematic review and meta-analysis to compare the clinical outcome of the use of short implants (≤6 mm) in atrophic posterior maxilla versus longer implants with sinus floor elevation. At 1 year or longer postloading, there is no significant difference in participant unit implant survival rate between the short implant group and the elevation group. The short implant group showed less MBL than the elevation group for 1--3 years follow-up (low-quality evidence) and 3 years or longer follow-up (moderate-quality evidence). In addition, the short implant group showed fewer postsurgery reaction and sinus membrane perforation and infection.

The survival rate in this review was evaluated by participant unit as in a previous Cochrane review.[@R34] In this review, the overall survival rates for the short implant group and the elevation group were 98.21% and 96.08%, respectively, at 1--3 years follow-up and 99.20% and 98.23%, respectively, at longer than 3 years follow-up; no significant difference in survival rate was found. Other studies that assessed survival rate in implant unit had similar outcomes. A retrospective study[@R47] with a follow-up period of 17--48 months reported a 95.12% implant unit survival rate for 5--6 mm short implants. A prospective study[@R6] of 2--3 years reported that 6 mm short implants with microrough surfaces achieved a 100% survival rate in posterior maxilla. Another retrospective study of 5--10 years[@R48] reported a 97% implant unit survival rate for 6 mm short implants supporting single crowns. All these results showed that short implants (≤6 mm) represent a promising rehabilitation method with respect to their short-term and long-term survival rates.

In this review, all of the failed short implants were 4 mm or 5 mm. Although the use of short implants (≤6 mm) could avoid complicated surgical procedures and related early failures, reduced implant length was still the major risk factor in survival rate. The authors of the included studies used wider implants (4--8 mm) to compensate for the short length of the implants. Finite element analyses showed that wider implants had increased functional surface area in cortical bone and decreased stress distribution on the implant neck; these qualities helped improve primary stability, produce a higher survival rate and reduce MBL.[@R49] However, it was not determined whether implant length or diameter contributed more to implant failure. Another factor was implant surface structure. Studies[@R53] have suggested that the implant surface influences bone-to-implant osseointegration, implant primary stability and MBL. In this review, implants 4 or 5 mm in length had novel surface structures, but they still presented a lower survival rate.

Significantly less MBL was found in the short implant group, and the difference was greater at the longer follow-up period. Additionally, in this review, 5 mm diameter implants tended to induce less MBL than 4 mm diameter implants. Implants $\leq$10 mm[@R19] and $\leq$8 mm[@R20] were reported to induce MBL similar to that of longer implants, while implants $\leq$7 mm[@R57] showed less MBL. These results contradict a previous theory that short implants are more likely to have an extreme crown-to-implant ratio (C/I)[@R58] that induces more peri-implant bone loss and early implant failure.[@R59] According to finite element analyses, inappropriate C/I results in adverse occlusal forces such as non-axial forces and overloading.[@R61] Increased C/I was also correlated with more prosthesis complications such as screw loosening, implant or abutment fracture, chipping of the ceramic material and prosthesis fracture.[@R62] However, the implants in the studies included in this systematic review had wider diameters (4--8 mm) and different surface structures. These two factors partially compensated for the complications of C/I and contributed to less MBL. Differences in implant diameter and surface structure also introduced heterogeneity among studies with respect to MBL. Short implants tolerated less MBL because of the limited implant length. As a result, less MBL was not necessarily correlated with better clinical outcome. MBL around short implants is still a challenging issue, and much effort should be made to resolve it.

With respect to complications, the use of short implants (≤6 mm) could decrease the incidence of postsurgery reactions and sinus membrane perforation and infection. Sinus membrane perforation was common in the elevation group.[@R14] This was in accordance with a previous study[@R66] that reported more complications in cases involving longer implants with sinus floor elevation and that the surgical procedure made a major contribution to such complications. In this study, incidence of other biological and technical complications was similar between the two groups. Implant migration into the sinus, often with the co-occurrence of sinus infection, had a higher prevalence in the elevation group. When implant migration occurs, implants may be removed, thus leading to implant failure.[@R67] Technical complications, including screw loosening, crown loosening and chipping, were mainly associated with inappropriate loading, which could be resolved by improving supra rehabilitation structure. In addition, for short implants (≤6 mm), risks relating to reduced length could be partially alleviated by improving the design of the implants[@R68] or increasing their diameter. With respect to the prevalence and severity of adverse events, the use of short implants (≤6 mm) was acceptable and was a promising alternative to sinus floor elevation.

The present study has several strengths. First, we conducted a comprehensive literature search, and all included studies were RCTs. Second, participant was used as the unit of analysis to ensure logical statistical syntheses and relevant interpretations. Third, subgroup analysis by follow-up length and categories of complications was performed to reduce bias across studies. However, the evidence included in this systematic review was only of moderate or low quality. Serious risks of bias were found within and across studies. The number of participants and the follow-up period were limited. Due to limited data and methodological heterogeneity among studies, data synthesis for patient satisfaction was not performed. We suggest that researchers in this field carry out more well-designed, long-term and large-scale RCTs to provide high-quality evidence regarding the effects of short implants (≤6 mm).

Conclusions {#s5}
===========

Within its limitations, the present review suggests that the survival rate of maxillary short implants (≤6 mm) was comparable to that of longer implants (≥10 mm) with sinus floor elevation. However, short implants (≤6 mm) show significantly less MBL and postsurgery reactions. Short implants (≤6 mm) are, therefore, the promising alternative to sinus floor elevation for posterior maxilla with insufficient bone volume. Additional high-quality studies are needed to evaluate the long-term effectiveness and safety of short implants (≤6 mm).
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